Roivant Sciences Ltd.
NASDAQ:ROIV
11.76 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Roivant Sciences Ltd. |
Symbool | ROIV |
Munteenheid | USD |
Prijs | 11.76 |
Beurswaarde | 8,696,778,720 |
Dividendpercentage | 0% |
52-weken bereik | 8.465 - 13.055 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Matthew Gline |
Website | https://roivant.com |
An error occurred while fetching data.
Over Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)